Tau genotype: No effect on onset, symptom severity, or survival in progressive supranuclear palsy

Neurology

Volumn 57, Issue 1, 2001, Pages 138-140

  Litvan, Irene ^a,c   Baker, Matt ^b   Hutton, Michael ^b  

^a Henry Jackson Foundation   (United States)

^b MAYO CLINIC   (United States)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAU PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC ANALYSIS; GENOTYPE; HUMAN; INHERITANCE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE SUPRANUCLEAR PALSY; SURVIVAL RATE;

EID: 0035838444     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.1.138     Document Type: Article

References (10)

1. Association of an extended haplotype in the tau gene with progressive supranuclear palsy
2. Genetic evidence for the involvement of tau in progressive supranuclear palsy
3. Apolipoprotein E epsilon 4 allele frequency is not increased in progressive supranuclear palsy
4. Apolipoprotein E epsilon 4 allele does not affect the onset or symptom severity in progressive supranuclear palsy
5. Progressive supranuclear palsy: Earlier age of onset in patients with the tau protein A0/A) genotype
6. The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases
7. Presymptomatic hypertension in progressive supranuclear palsy
8. Presymptomatic hypertension is a major feature in the diagnosis of progressive supranuclear palsy
9. Atypical parkinsonism in Afro-Caribbean and Indian origin immigrants to the UK
10. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias